Cary Street Partners Investment Advisory’s West Pharmaceutical WST Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-518	Closed	-$205K	–	767
2024 Q1	$205K	Sell	518 -252	-33%	-$93.2K	0.01%	669
2023 Q4	$271K	Buy	770 +497	+182%	+$176K	0.01%	547
2023 Q3	$102K	Sell	273 -2	-0.7%	-$773	0.01%	698
2023 Q2	$105K	Sell	275 -25	-8%	-$8.93K	0.01%	652
2023 Q1	$104K	Sell	300 -65	-18%	-$19K	0.01%	584
2022 Q4	$85.9K	Buy	+365	New	+$86.5K	0.01%	619

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cary Street Partners Investment Advisory's WST Position: Q2 2024 in Review

Cary Street Partners Investment Advisory sold out of West Pharmaceutical (WST) in Q2 2024, closing a stake of 518 shares — an estimated $205K sold.

Cary Street Partners Investment Advisory first reported a position in WST in Q4 2022 and held it in 6 quarters. The position peaked at $271K in Q4 2023. 777 funds tracked by Wall St. Rank hold WST as of Q2 2024.

Cary Street Partners Investment Advisory reported no remaining West Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Cary Street Partners Investment Advisory sold 518 West Pharmaceutical shares in Q2 2024, an estimated $205K.
Cary Street Partners Investment Advisory first reported a position in West Pharmaceutical in Q4 2022 and held it in 6 quarters.
Cary Street Partners Investment Advisory's West Pharmaceutical position peaked at $271K in Q4 2023.
777 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2024.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2024, filed 22 Jul 2024.